Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.
Androdias G, Lünemann JD, Maillart E, Amato MP, Audoin B, Bruijstens AL, Bsteh G, Butzkueven H, Ciccarelli O, Cobo-Calvo A, Derfuss T, Di Pauli F, Edan G, Enzinger C, Geraldes R, Granziera C, Hacohen Y, Hartung HP, Hynes S, Inglese M, Kappos L, Kuusisto H, Langer-Gould A, Magyari M, Marignier R, Montalban X, Mycko MP, Nourbakhsh B, Oh J, Oreja-Guevara C, Piehl F, Prosperini L, Sastre-Garriga J, Sellebjerg F, Selmaj K, Siva A, Tallantyre E, van Pesch V, Vukusic S, Weinstock-Guttman B, Zipp F, Tintoré M, Iacobaeus E, Stankoff B. Androdias G, et al. Among authors: di pauli f. Brain. 2024 Dec 21:awae409. doi: 10.1093/brain/awae409. Online ahead of print. Brain. 2024. PMID: 39707906
Multiple sclerosis and COVID-19: How many are at risk?
Bsteh G, Bitschnau C, Hegen H, Auer M, Di Pauli F, Rommer P, Deisenhammer F, Berger T. Bsteh G, et al. Among authors: di pauli f. Eur J Neurol. 2021 Oct;28(10):3369-3374. doi: 10.1111/ene.14555. Epub 2020 Oct 22. Eur J Neurol. 2021. PMID: 32978860 Free PMC article.
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, Iacobaeus E, Mycko M, Abboud H, Achiron A, Bellinvia A, Boyko A, Casanova JL, Clifford D, Dobson R, Farez MF, Filippi M, Fitzgerald KC, Fonderico M, Gouider R, Hacohen Y, Hellwig K, Hemmer B, Kappos L, Ladeira F, Lebrun-Frénay C, Louapre C, Magyari M, Mehling M, Oreja-Guevara C, Pandit L, Papeix C, Piehl F, Portaccio E, Ruiz-Camps I, Selmaj K, Simpson-Yap S, Siva A, Sorensen PS, Sormani MP, Trojano M, Vaknin-Dembinsky A, Vukusic S, Weinshenker B, Wiendl H, Winkelmann A, Zuluaga Rodas MI, Tintoré M, Stankoff B. Tur C, et al. Among authors: di pauli f. Mult Scler. 2022 Aug;28(9):1424-1456. doi: 10.1177/13524585211069068. Epub 2022 Feb 23. Mult Scler. 2022. PMID: 35196927 Review.
Sex impacts treatment decisions in multiple sclerosis.
Hegen H, Berek K, Deisenhammer F, Berger T, Enzinger C, Guger M, Kraus J, Walde J, Di Pauli F. Hegen H, et al. Among authors: di pauli f. J Neurol. 2024 Jun;271(6):3256-3267. doi: 10.1007/s00415-024-12270-y. Epub 2024 Mar 5. J Neurol. 2024. PMID: 38441611 Free PMC article.
Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
Guger M, Enzinger C, Leutmezer F, Di Pauli F, Kraus J, Kalcher S, Kvas E, Berger T; Austrian MS Treatment Registry (AMSTR). Guger M, et al. Among authors: di pauli f. J Neurol. 2021 Nov;268(11):4303-4310. doi: 10.1007/s00415-021-10559-w. Epub 2021 Apr 22. J Neurol. 2021. PMID: 33890167 Free PMC article.
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: di pauli f. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
Guger M, Enzinger C, Leutmezer F, Di Pauli F, Kraus J, Kalcher S, Kvas E, Berger T; Austrian MS Treatment Registry (AMSTR). Guger M, et al. Among authors: di pauli f. J Neurol. 2023 Jun;270(6):3103-3111. doi: 10.1007/s00415-023-11644-y. Epub 2023 Mar 2. J Neurol. 2023. PMID: 36862148 Free PMC article.
102 results